HLA-DRB1 and disease outcome in multiple sclerosis

Area of Science:

• Immunogenetics
• Neurology
• Human Genetics

Background:

• The HLA-DRB1*15 allele is a known susceptibility factor for multiple sclerosis (MS).
• Its association with MS disease progression and severity remains unclear.
• Previous studies suggest potential roles for other HLA alleles (e.g., HLA-DRB1*03, HLA-DRB1*04).

Purpose of the Study:

• To investigate the association between HLA-DRB1*15 and clinical outcomes in multiple sclerosis.
• To examine the influence of HLA-DRB1*15 on disease severity and progression.
• To explore the impact of other HLA alleles (HLA-DRB1*03, HLA-DRB1*04) on MS.

Main Methods:

• HLA-DRB1 genotyping was performed on 375 white MS patients and 367 healthy controls.
• Patients were categorized by Expanded Disability Status Scale (EDSS) scores (mild/moderate vs. severe).
• Analyses considered disease duration (≥10 years, ≥15 years) to account for variability.

Main Results:

• HLA-DRB1*15 was significantly more frequent in MS patients than controls (P < 0.000001).
• HLA-DRB1*15 positive patients exhibited a significantly earlier age of MS onset.
• No significant association was found between HLA-DRB1*15 and MS outcome in the overall group or with disease duration of 10+ years.
• A trend towards worse prognosis in HLA-DRB1*15 negative patients with disease duration of 15+ years was observed but not statistically significant after correction.

Conclusions:

• The primary role of HLA in MS appears to be related to susceptibility and initial disease triggering.
• HLA-DRB1*15 is strongly associated with increased risk and earlier onset of multiple sclerosis.
• Evidence does not support a significant role for HLA-DRB1*15 in influencing MS disease progression, chronicity, or severity.